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Abstract Thrombotic risk increases in elderly,
therefore, the understanding of the genetic predispo-
sition of hypercoagulability could make the difference
in the prevention of venous and/or arterial thrombotic
events. Laboratory evaluation of hyperfibrinogene-
mia, increased Factor VII levels, antiphospholipid
antibodies presence and hyperhomocysteinemia are
considered to have a consistent high predictivity for
arterial thrombophilic diseases. Anyway, a large
debate exists on the validity of testing Leiden Factor
V (FV) G1691A and/or prothrombin (FII) G20210A
polymorphisms in patients affected by arterial throm-
botic diseases, despite of the several observations
described. Here we report data strongly suggesting
that at least the FII G20210A polymorphism might be
considered an important risk factor for acute myocar-
dial infarction in aged patients (55–80 years old). On
the other hand, in spite of a not different genotypic and
allelic distribution for the Leiden FV G1691A muta-
tion, the presence of one or both the two polymor-
phisms is significantly higher among cases than in
controls. In conclusion, our data suggest that FII
G20210A and/or Leiden FV might be involved as risk
factor for arterial disorders in about 5% of old
subjects, justifying the opportunity of a genetic
screening and an eventual preventive treatment, in
particular in old subjects in which other and major risk
factors, as hypertension and atherosclerosis, are
detected.
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Introduction
It is well known that thrombotic risk increases in
elderly, as physiological aging is associated with
increased plasma levels of many blood coagulation
proteins, with alterations of platelets and fibrinolysis
impairment (Mari et al. 2008), so that pathologies as
atherosclerosis, cardiovascular disease or stroke are
typically considered aging associated diseases.
Therefore, the understanding of the genetic predis-
position of hypercoagulability could make the differ-
ence in the prevention of venous and/or arterial
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thrombotic events, with high benefits in health costs.
According to this view, several scientific societies
involved in this field have elaborated guidelines
suggesting a list of recommended tests for the
screening of congenital or acquired thrombophilic
diseases (De Stefano et al. 1996; Lane et al. 1996) in
categories of risk patients. In addition, in different
studies mutations of genes not involved in clot
formation and regulation have been found to play a
crucial role in the susceptibility for arterial thrombotic
disorders (Lio et al. 2004; Listı` et al. 2008; Billeci
et al. 2009), but generally they’re not retained useful in
public health programs for the risk’s evaluation
profile, due to their modest contribution to the
benefits/costs balance.
Actually, in order to test the congenital or acquired
predisposition to the deep venous thrombosis, muta-
tions occurring on genes coding for antithrombin III
(AT), protein C (PC), protein S (PS), Leiden Factor V
(FV) and prothrombin (FII) G20210A, or their defi-
ciency, plus dysfibrinogenemia, hyperhomocystein-
emia or antiphospholipid antibodies presence, are
currently searched in patients undergoing surgery,
pregnant or using oral contraceptives women, patients
with family history, previous episodes or youth’s
events (Testa et al. 2004; Tripodi and Mannucci 2001).
Whereas, as it is largely recognized, only hyperfi-
brinogenemia, increased Factor VII (FVII) levels,
antiphospholipid antibodies presence and hyperhom-
ocysteinemia are considered to have a consistent high
predictivity for the susceptibility to arterial thrombo-
philic diseases (Van Cott et al. 2002; Kahn 2003).
However, although several studies have observed
an association of Leiden FV and FII G20210A with
arterial thrombotic disorders, especially in the associ-
ation with the juvenile cases (Kim and Becker 2003),
and it has been reported that these tests can be
considered useful in certain situations, such as in the
evaluation of the risk profile of young patients and/or
in their relatives (Soo and Davidson 2007), there is no
consistent evidence for the recommendation of routine
typing for Leiden FV, FII, AT III, PC and PS in
patients having risk of stroke or arterial thrombotic
disease (Ridker et al. 1995; Tripodi and Mannucci
2001; Ridker et al. 1999).
Moreover, a strong coagulatory potential increasing
characterizes elderly, so that age itself plays an
important role as risk factor in the onset of thrombo-
embolic diseases, added to other risk factors as
smoking, hypertension or diabetes, anyway, the con-
tribution of genetic polymorphisms and in particular
of Leiden FV and FII G20210A to the susceptibility to
arterial thrombotic events in old people remain to be
demonstrated.
Here, we report data on the evaluation of the
frequencies of polymorphisms FV G1691A and FII
G20210A in a group of 164 patients aged between 55
and 80 years old, affected by acute myocardial
infarction (AMI), to give an insight on the opportunity
to execute this genetic tests on restricted category of
risk’s patients in advanced age, in order to provide an
instrument to clinicians to act in the prevention of the
thrombotic event.
Materials and methods
Subjects
In this study, we analyzed a cohort of patients affected
by acute myocardial infarction and one other of
unrelated age matched controls. The cohort comprised
164 patients aged between 55–80 years old with a mean
age of 67 years, of which 80% were male, affected by
acute myocardial infarction, who were diagnosed at the
cardiac unit of Bologna University Hospital. The
diagnosis of acute myocardial infarction was based on
typical electrocardiographic changes and standard
laboratory findings, in particular troponin I value
greater than a decision limit of 3.0 ng/ml, (Peetz et al.
2006), confirmed by echocardiography and coronary
angiography. 253 controls matched for age, of which
about 75% were male from the same geographic origin,
who had no clinical history of age related diseases were
also recruited. Informed consent to recruitment in the
study was obtained from each subject according to
European guidelines and Italian laws.
G1691A of FV and 20210GA of FII Allele
Discrimination assay
The blood specimens were collected in EDTA sterile
tubes, and stored in freezer at -20C. Then, DNA was
extracted using a salting out protocol (Miller et al.
1988), resuspended in Tris–EDTA buffer and stored at
-20C. Typing of FV mutation was performed for 214
out of 253 control’ and 149 out of 164 patient’ DNA
samples, whereas 222 out of 253 controls and 150 out
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of 164 patients were typed for FII polymorphism.
Among these, 207 out of 253 controls and 148 patients
out of 164 were typed for both the two gene variants.
Two dedicated and pre-made Taqman Assays
developed by Applied Biosystem (USA) were used
to perform the Allelic Discrimination tests for the
typing of the polymorphisms FV G1691A and FII
G20210A.
Briefly, 10 ng of DNA for each sample were used in
a PCR reaction, containing 19 optimized master mix
and 19 specific primers/probes mix assay, according
to manufactory protocol in a final volume of 25 ll.
For each polymorphism two identical probes,
except for the central nucleotide that specifically
recognizes the single nucleotide polymorphism (SNP)
were used, each one labeled at the 50 extremity with
different dyes, FAM and VIC in this case, and at the 30
extremity with a quencher dye, that in this case was the
Minor Groove Binder (MGB) dye.
Then, the amplification was performed in 7300 Real-
Time ABI Prism PCR System (Applied Biosystems,
USA), using a standard amplification protocol (1 cycle
of 20 at 50C; 1 cycle of 100 at 95C and 40 cycles of 1500
at 95C plus 1500 at 60C), and the results available in
the report sheet of 7300 System SDS v1.3 Software.
Moreover, samples were graphically grouped in
three genotypic clusters, easily recognizable in the
Allelic Discrimination plot on the basis of the two
probe’s fluorescence intensity emissions, whereas the
uncertain cases were also evaluated for the grow up of
the fluorescence emission curve of each dyes on the
component’s sheet.
Statistical analysis
The data were tested for goodness of fit between the
observed and expected genotype (3 9 2 tables) and
allele (2 9 2 tables) frequencies. Fisher’s exact tests
were performed to calculate significant different geno-
type or allelic distributions between patients with acute
myocardial infarction and age matched controls. Odds
ratio and 95% of confidence intervals were calculated
with Woolf’s approximation to quantify the risk in
carriers of minor allelic variants. Mantel–Haenszel
procedure for the trend analysis was applied to evaluate
the effect of gene polymorphism combinations.
Results
Table 1 shows the analysis of genotypic and allelic
frequencies of the single nucleotide polymorphism
located at the position G20210A of the prothrombin
(FII) 30UTR region among the 150 patients and 222
healthy controls. Both patient’ and control’ genetic
frequencies fit the Hardy–Weinberg equilibrium. We
observed a considerable significant increase of the
minor allele (A) (P = 0.0031), that is represented with
a percentage of 5.3% among patients, against 1.35%
among the healthy controls. Accordingly, a significant
different genotypic distribution characterized by a
consistent increase of the A positive subjects (10.0 vs.
2.7%) (P = 0.0048, Odds ratio 4.00; 95% Confidence
Interval 1.51–10.56) is also observable.
Instead, genotypic and allelic distribution were not
different for the polymorphism Leiden FV G1691A
between patients and controls, (P [ 0.05), as the allele
frequency in patients was 2.7%, overlapping that one
observable for the control group (2.1%) (Table 2).
On the other hand, it is well known that the
protection or susceptibility effect of a single polymor-
phism might be modulated by both an additive/synergic
or antagonistic pressure through the presence of other
polymorphisms in genes involved in the same
Table 1 FII 20210G ? A. Genotypic and allelic frequencies of polymorphism G20210A of prothrombin gene observed in 150
over-fifty-five acute myocardial infarction affected patients and healthy age matched controls
N Genotype frequencies Allele frequencies
G/G G/A** A/A** G A*
Cases 150 90% (135) 9.3% (14) 0.7% (1) 94.7% (284) 5.3% (16)
Controls 222 97.3% (216) 2.7% (6) 0% (0) 98.65% (438) 1.35% (6)
*20210A allele frequency was found significantly increased in the patients group vs. controls.** Accordingly, a significant increase
of the percentage of acute myocardial infarction patients carrying A positive genotypes was observed (P = 0.0048, Odds ratio 4.00;
95% Confidence Interval 1.51–10.56)
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metabolic or functional pathway. In this view, we tested
the hypothesis that the presence of both the two
mutations could increase the risk of susceptibility or
onset of cardiovascular events. In particular, Mantel–
Haenszel procedure allows to find a significant trend for
the increase of single and double locus heterozygosis in
patients affected by acute myocardial infarction
(P = 0.013), with a cumulative odds ratio of 2.79
(95% Confidence Interval 1.28 to 6.05) (Table 3).
Actually, among 148 patients that it was possible to test,
5 patients carrying both the two mutations in hetero-
zygosis were found. Furthermore, also the presence of
at least one of the two polymorphisms in heterozygosis
(FV G1691A or FII G20210A) is prevalent among
cases (7.3%) than in controls (6.3%). The calculated
odd ratio for the presence of at least one mutation is
1.82 (95% C.I. 0.8483 to 3.916), while in the presence
of double heterozygous condition the odd ratio became
16.018 (95% C.I. 0.8782 to 292.16).
Discussion
Susceptibility to the onset of arterial disorders are
surely conditioned by the presence of clinical/envi-
ronmental risk factors, such as smoking, advanced
age, elevated cholesterol/LDL plasma levels, hyper-
tension, diabetes, that strongly predispose to arterial
thrombotic events.
A large debate exists on the risk association among
Leiden Factor V (FV) G1691A and/or prothrombin
(FII) G20210A polymorphisms and arterial disorders,
despite of the several observations reported in a
consistent collection of literature’s papers showing
data regarding different cohorts of patients affected by
arterial thrombotic diseases, having different age ranges
and geographical proveniences (Mazoyer et al. 2009;
Kahn 2003; Ridker et al. 1995; Ozmen et al. 2009;
Ridker et al. 1999; Kim and Becker 2003; Soare and
Popa 2010).
Nevertheless, it has been supposed that there are not
enough evidence for the suggestion of diagnostic
investigation of these mutations, whereas guidelines
only suggest the execution of other tests that are
considered to have a major predictive value, such as
hyperfibrinogenemia, increased Factor VII levels,
antiphospholipid antibodies presence and hyperhom-
ocysteinemia (Soo and Davidson 2007, Tripodi and
Mannucci 2001).
Significant association among Leiden FV and FII
G20210A and stroke in young\50 years old patients
have been described (Kim and Becker 2003; Gemmati
et al. 2001; Soare and Popa 2010). So these mutations
could make the difference for the susceptibility to
stroke in patients in which there are not yet compli-
ances generated by age-related defects and diseases
and may justify the evaluation of these genetic factors
both in patients and their relatives. This is at least
Table 2 FV 1691G ? A. Genotypic and allelic frequencies of polymorphism G1691A of Factor V gene observed in 150 over- fifty-
five acute myocardial infarction affected patients and healthy age matched controls
N Genotype frequencies Allele frequencies
G/G G/A A/A G A
Cases 149 94.6% (141) 5.4% (8) 0% (0) 97.3% (290) 2.7% (8)
Controls 214 95.8% (205) 4.2% (9) 0% (0) 97.9% (419) 2.1% (9)
Genotypic and allelic distribution were not different between patient and control groups
Table 3 FV G1691A and FII G20210A combinations. Analysis of genotypic combinations of polymorphisms FV G1691A and FII
G20210A observed in 148 over- fifty-five acute myocardial infarction affected patients and healthy age matched controls
N Genotypic frequencies
FVG1691 and FIIG20210
homozygous wild type
Single locus
heterozygosis*
Double locus
heterozygosis*
Single locus minor
allele homozygosis
Double locus minor
allele homozygosis
Cases 148 88.5% (131) 7.4% (11) 3.4% (5) 0.7% (1) 0% (0)
Controls 207 93.5% (194) 6.5% (13) 0% (0) 0% (0) 0% (0)
*Mantel–Haenszel procedure allows to find a significant trend for the increase of single and double locus heterozygosis in patients
affected by acute myocardial infarction (P = 0.0113), the cumulative odd ratio is 2.79 (95% Confidence Interval 1.28 to 6.05)
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reputed licit by some authors (Soo and Davidson
2007).
As well known, hypercoagulability, remains an
important cause of haemostatic unbalance, growing
with age advancing (Mari et al. 2008), but data on the
impact of these two mutations on arterial disorders risk
on selected cohort of aged patients are not exhaustive.
Here we report data strongly suggesting that at least the
FII G20210A polymorphism might be considered a risk
factor for acute myocardial infarction (AMI) in aged
patients (55–80 years old). Actually, we observed a
significant increase of 20210A FII allele associated to
the reported higher plasma prothrombin level respect to
the wild type ones (Mazoyer et al. 2009).
The presence of G 20210 A substitution in the 30
upstream untranslated region of prothrombin gene
seems to play a regulatory role in gene expression
(Poort et al. 1996). Actually, the G to A transition at
nucleotide position 20,210, at or near the cleavage site
of the mRNA precursor, to which poly A is added,
seems to stabilize mRNA allowing an increased
production of the corresponding protein (Poort et al.
1996).
The biological plausibility that a higher prothrom-
bin level related to the 20210A variant may also confer
an increased risk of arterial disease seems well
supported by studies in which an excessive thrombin
generation has been described in individuals at high
risk of fatal coronary artery disease (Miller et al.
1996). To date, however, studies attempting to answer
this question have yielded conflicting results. In some
reports, being a carrier of the mutation was associated
with an increased risk of AMI (Franco et al. 1999;
Miller et al. 1996). Other studies failed to establish any
association between the 20210A allele and AMI.
(Russo et al. 2001; Ridker et al. 1999).
On the other hand, as above described, in spite of a
similar genotypic and allelic distribution observed for
the Leiden FV G1691A mutation, the percentage of
patients bearing one or both the two polymorphisms is
more or significantly increased respect to the controls.
As it is known, an adenine instead of a guanine
replacement in the position 1,691 of FV gene intro-
duces a critical aminoacid change in the protein
(Arg506Gln), that make the FV resistant to the attack
of PC, producing an increasing of hypercoagulability
(De Stefano and Leone 1995).
As reported by Gemmati et al. (2001), in a family
clinical study it was observed that a patient, who
exhibited combined heterozygosis for FV G1691A
and FII G20210A mutations, was affected by sponta-
neous and early clinical onset recurrences of deep-vein
thrombosis and pulmonary embolism and similar data
was described among the relatives (Gemmati et al.
2001). This case report seems to suggest that the
synergy of inherited factors and transient risk condi-
tions could play a key role in the occurrence of
thrombotic accidents.
Our results seem to suggest that individuals carriers
for double combined heterozygous FV G1691A and
FII G20210A mutations may be particularly suscep-
tible to AMI.
The possibility that this selection could be related to
the age range of individuals analyzed should be taken
in account. Beside, we matched for age our group of
controls. Moreover, in previous studies we did not
observe differences in genotype and allele frequencies
in populations stratified for age, as centenarians
([90 years old) had similar frequencies respect to
young controls (Forte et al. 2009). Accordingly, no age
stratification difference was observed in a study
involving 6,154 French individuals. (Mazoyer et al.
2009) .
In conclusion, our data seem to suggest that
prothrombin G20210A variant alone or in combina-
tion with Leiden FV might be involved as risk factor
for AMI in about 5% of subjects[55 years old.
However, as above reported, previous studies have
shown negative associations among cardiovascular
events and prothrombin G20210A and/or Leiden FV
polymorphisms. In this view, the relatively small
number of subjects typed for the two polymorphisms
in our study might affect the strength of the statistical
comparison. So, our data necessitate to be confirmed
in a larger population of aged people. This should be
taken in account before to draw definitive conclusions
on the opportunity of a genetic screening and an
eventual preventive treatment, in particular in old
subject population in which other and major risk
factors as hypertension and atherosclerosis are com-
monly detected.
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